IL6 and neoplasm: DCs in MM patients are a target of tumor-associated suppressive factors, such as IL-10, TGF-β, VEGF, and IL-6, resulting in their aberrant functions and impaired development of effector functions in tumor-specific lymphocytes [55, 56].